Bio-Techne (NASDAQ:TECH – Get Free Report) and Elevation Oncology (NASDAQ:ELEV – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.
Institutional and Insider Ownership
98.9% of Bio-Techne shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 3.9% of Bio-Techne shares are owned by company insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Bio-Techne and Elevation Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Techne | $1.17 billion | 10.20 | $168.10 million | $0.94 | 79.99 |
| Elevation Oncology | N/A | N/A | -$45.70 million | ($0.82) | -0.92 |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Bio-Techne and Elevation Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Techne | 0 | 3 | 5 | 0 | 2.63 |
| Elevation Oncology | 0 | 0 | 6 | 0 | 3.00 |
Bio-Techne presently has a consensus price target of $82.00, suggesting a potential upside of 9.06%. Elevation Oncology has a consensus price target of $7.20, suggesting a potential upside of 855.16%. Given Elevation Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Elevation Oncology is more favorable than Bio-Techne.
Profitability
This table compares Bio-Techne and Elevation Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Techne | 12.86% | 12.76% | 9.59% |
| Elevation Oncology | N/A | -59.73% | -40.05% |
Volatility and Risk
Bio-Techne has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Summary
Bio-Techne beats Elevation Oncology on 8 of the 13 factors compared between the two stocks.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
About Elevation Oncology
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
